Le Lézard
Classified in: Health
Subject: CCA

Neovasc to Host Third Quarter 2017 Conference Call



NASDAQ, TSX: NVCN

VANCOUVER, Nov. 10, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call that same day at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive Officer, and Mr. Chris Clark, Chief Financial Officer. A question and answer session will follow the corporate update.

Conference Call Details


DATE:

Tuesday, November 14, 2017

TIME:

4:30 pm ET

DIAL-IN NUMBER:

888 390 0605 or 416 764 8609

 

A link to the live audio webcast of the conference call will also be available on the Presentations and Events page of the Investors section of Neovasc's website at www.neovasc.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.  

A recording of the call will be available for 72 hours by calling 888 390 0541 or 416 764 8677 and using passcode 762334#.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducertm, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiaratm, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.


These press releases may also interest you

at 21:59
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Plasma Protease C1-inhibitor Treatment Market: OverviewThis report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of...

at 21:37
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Ophthalmic Surgical Technologies Market: OverviewThe global ophthalmic surgical technologies market report provides a clear picture of the comprehensive dynamics of the market. The ophthalmic surgical...

at 21:21
LONDON, Nov. 20, 2017 /PRNewswire/ -- "Global tissue diagnostics market projected to grow at a CAGR of 6.9% during the forecast period" Download the full report: https://www.reportbuyer.com/product/5206184The tissue diagnostics market is expected to...

at 21:19
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Tattoo Removal Devices Market: OverviewThe report on the global tattoo removal devices market offers a critical evaluation of key factors and notable trends influencing the growth of the market. The study...

at 21:18
NEW YORK, Nov. 20, 2017 /PRNewswire/ -- Weight Watchers International, Inc. (NYSE: WTW) (the "Company") announced today that it has priced $300.0 million in aggregate principal amount of its 8.625% senior notes due 2025 (the "Notes") in a private...

at 21:17
LONDON, Nov. 20, 2017 /PRNewswire/ -- Global Stretch Marks Treatment Market: OverviewStretch marks also known as striae are commonly observed during or after pregnancy, during puberty, or a sudden change in weight. These marks appear due to the...




News published on 10 november 2017 at 14:56 and distributed by: